EGFR Antibody [H9B4]

Primary Antibodies

Aliquot and Store at 2-8˚ C. Avoid freez-thaw cycles.

Epidermal Growth Factor Receptor is a type I receptor tyrosine kinase, referred to as EGFR, ErbB1 and HER1. When EGFR is activated by one of its ligands, it dimerizes. It can form a homodimer, heterodimers with other ErbB family members, or even a cluster of EGFRs. Activation stimulates EGFRs intracellular kinase activity. Autophosphorylation of tyrosine residues in the C-terminal domain of EGFR leads to association with proteins with phosphotyrosine-binding domains which then signal the initiation of signal transduction cascades including the JNK, MAPK, AKT, and possibly Nf-KB, pathways. Overexpression of EGFR is the cause of some types of cancer, including lung and colon cancer. It has also been linked to psoriasis, eczema and atherosclerosis, although poorly defined. Monoclonal antibody to EGFR can be used to block the extracellular ligand binding domain, therebye blocking tyrosine kinase activation and subsequent signal transduction.

None

0.2 mg/mL

IP: 1-2µg/500ug protein lysate
WB: 0.5-1 ug/ml
Titration of the antibody may be required for optimal performance.

1. This antibody reacts with a cytoplasmic domain of EGFR.

Purified EGFR from A431 cells was used as the immunogen for this antibody. (1)

epidermal growth factor receptor

Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.